Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 15.16
- Piotroski Score 8.00
- Grade Overweight
- Symbol (ADMA)
- Company ADMA Biologics, Inc.
- Price $19.99
- Changes Percentage (3.12%)
- Change $0.61
- Day Low $19.27
- Day High $20.37
- Year High $20.37
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $9.25
- High Stock Price Target $14.00
- Low Stock Price Target $4.50
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.02
- Trailing P/E Ratio -523.5
- Forward P/E Ratio -523.5
- P/E Growth -523.5
- Net Income $-28,239,000
Income Statement
Quarterly
Annual
Latest News of ADMA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is ADMA Biologics Inc. (ADMA) the Best Performing Small-Cap Stock in 2024?
The article discusses the performance of small-cap stocks in 2024, with a focus on ADMA Biologics Inc. It highlights market trends, insights from Richard Bernstein, and the company's financial growth....
By Yahoo! Finance | 4 days ago -
Millennium Management LLC Acquires Shares in ADMA Biologics Inc
In September 2024, Millennium Management LLC acquired 1,374,038 shares of ADMA Biologics Inc, a biopharmaceutical player, at $19.74 per share, signaling a strategic move into the healthcare industry....
By Yahoo! Finance | 1 week ago -
Cooking host Padma Lakshmi: Harris' culinary skills 'might say even more about her success as a leader'
Padma Lakshmi praises Kamala Harris' cooking skills, stating it reflects her leadership qualities. Harris' passion for cooking humanizes her and connects her with voters. Lakshmi believes Harris' appr...
By Fox News | 1 week ago
